Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells attack many tumour cell lines, and are thought to have a critical role in anti-tumour immunity; however, the interaction between NK cells and tumour targets is poorly understood. The stimulatory lectin-like NKG2D receptor is expressed by NK cells, activated CD8+ T cells and by activated macrophages in mice. Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identified, some of which are expressed at high levels by tumour cells but not by normal cells in adults. However, no direct evidence links the expression of these 'induced self' ligands with tumour cell rejection. Here we demonstrate that ectopic expression of the murine NKG2D ligands Rae1beta or H60 in several tumour cell lines results in potent rejection of the tumour cells by syngeneic mice. Rejection is mediated by NK cells and/or CD8+ T cells. The ligand-expressing tumour cells induce potent priming of cytotoxic T cells and sensitization of NK cells in vivo. Mice that are exposed to live or irradiated tumour cells expressing Rae1 or H60 are specifically immune to subsequent challenge with tumour cells that lack NKG2D ligands, suggesting application of the ligands in the design of tumour vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
In the citing paper
“Previous studies from our laboratory demonstrated that transplanted tumor cells expressing NKG2D ligands are rejected by NK cells and, in some cases, T cells (Diefenbach et al., 2000, 2001, 2003)”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818 · cited 1×
“However, this was not the case with irradiated ligand-negative B16-BL6 tumour cell”
BackgroundInnate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection
Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac, A. J., Miller, J. D., Slansky, J., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80470-7 · Cited by 1,943 · cited 1×
“IFN-γ production was assayed by stimulating CTLs or NK cells with an equal number of target cells for 5–7 h and staining intracellular IFN-γ as describe”
MethodActivating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778 · cited 1×
“It is unknown whether engagement of NKG2D in NK cells results in direct stimulation or supplies a co-stimulatory signal that acts in conjunction with signals from other stimulatory receptor”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232 · cited 1×
“Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identifie”
BackgroundRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 101–200 of 1,000
A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
Deng, W., Gowen, B. G., Zhang, L., Wang, L., Lau, S., Iannello, A., Xu, J., Rovis, T. L., Xiong, N., & Raulet, D. H. (2015) · Science · doi:10.1126/science.1258867 · Cited by 255
“Pools correspond to >85 kD (1-10), ~65-85 kD (11-20), ~50-65 kD (21-30), ~35-50 kD (31-40), ~20-35 kD (41-50), <20 kD (51-60).”
Self-citationProteolytic Release of Soluble UL16-Binding Protein 2 from Tumor Cells
Waldhauer, I., & Steinle, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2520 · Cited by 245
“NKG2DL expression is induced by carcinogens and genotoxic stress, and tumor cell lines transduced with mouse NKG2DL were readily eliminated in vivo due to NK and CD8 T-cell activity and induced tumor immunity against the parental cell line (6, 9, 10).”
BackgroundInnate and adaptive immunity: specificities and signaling hierarchies revisited
Vivier, E., & Malissen, B. (2005) · Nature Immunology · doi:10.1038/ni1153 · Cited by 246
“This enables MHC class I-positive cells to serve as NK cell targets, as long as sufficient activating signals are provided 44, 45 .”
Macrophages as mediators of tumor immunosurveillance
Jaiswal, S., Chao, M. P., Majeti, R., & Weissman, I. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.001 · Cited by 246
“12 Diefenbach, A. et al. (2001) Rae1 and H60 ligands of the NKG2D”
Stebbins, C. C., Watzl, C., Billadeau, D. D., Leibson, P. J., Burshtyn, D. N., & Long, E. O. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6291-6299.2003 · Cited by 245
“receptors (3, 17, 25), could be explained by a DAP10/phospha-”
Backgroundde Pillis, L. G., Gu, W., Fister, K. R., Head, T., Maples, K., Murugan, A., Neal, T., & Yoshida, K. (2007) · Mathematical Biosciences · doi:10.1016/j.mbs.2006.05.003 · Cited by 245
In Vivo Survival and Homeostatic Proliferation of Natural Killer Cells
Prlic, M., Blazar, B. R., Farrar, M. A., & Jameson, S. C. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021847 · Cited by 243
NKG2D ligands: key targets of the immune response
González, S., López-Soto, A., Suarez-Alvarez, B., López-Vázquez, A., & López-Larrea, C. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.04.007 · Cited by 241
Soluble MICA in malignant diseases
Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A., & Salih, H. R. (2006) · International Journal of Cancer · doi:10.1002/ijc.21382 · Cited by 240
“In mice, NKG2DL expression by tumor cells strongly stimulates antitumor immunity, leading to tumor rejection by NK cells and/or CD8 T cells.(5,6) Because the strength of the antitumor response is critically dependent on NKG2DL surface levels,(5) downregulation of NKG2DL expression likely constitutes a novel tumor immu…”
BackgroundSystemic NKG2D Down-Regulation Impairs NK and CD8 T Cell Responses In Vivo
Wiemann, K., Mittrücker, H.-W., Feger, U., Welte, S. A., Yokoyama, W. M., Spies, T., Rammensee, H.-G., & Steinle, A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.720 · Cited by 240
“Previous studies also demonstrated that ectopic expression of NKG2DL by tumors induces strong NK and CTL responses in vivo and that rejection of NKG2DL-expressing tumor cells is perforin-dependent (25, 26, 44).”
BackgroundInfluentialNKG2D and its ligands in cancer
Dhar, P., & Wu, J. D. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.02.004 · Cited by 239
“Ectopic expression of a NKG2D ligand alone on tumor cells was sufficient to induce tumor rejection, through activation of NK and in some cases CD8 T cells [53,54].”
Cancer immunotherapy: The past, the present and the future
Parish, C. R. (2003) · Immunology & Cell Biology · doi:10.1046/j.0818-9641.2003.01151.x · Cited by 239
Hilpert, J., Grosse-Hovest, L., Grünebach, F., Buechele, C., Nuebling, T., Raum, T., Steinle, A., & Salih, H. R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200796 · Cited by 238
“When leukemia cells expressed more than one NKG2DL, additive effects were observed upon blocking several ligands, which is in line with data demonstrating that NK reactivity critically depends on NKG2DL expression levels (17, 18).”
BackgroundDiermayr, S., Himmelreich, H., Durovic, B., Mathys-Schneeberger, A., Siegler, U., Langenkamp, U., Hofsteenge, J., Gratwohl, A., Tichelli, A., Paluszewska, M., et al. (2008) · Blood · doi:10.1182/blood-2007-07-101311 · Cited by 220
“It is also noteworthy, that treatment with VA in some cases even enhanced the killing of blasts by HLA-class I matched NK cells, indicating that activating signals may override the negative KIR signaling, as described with murine NKG2D-L-overexpressing tumor targets.(51) According to our preliminary data, VA treatment…”
ResultDC-NK cell cross talk as a novel CD4+ T-cell–independent pathway for antitumor CTL induction
Adam, C., King, S., Allgeier, T., Braumüller, H., Lüking, C., Mysliwietz, J., Kriegeskorte, A., Busch, D. H., Röcken, M., & Mocikat, R. (2005) · Blood · doi:10.1182/blood-2004-09-3775 · Cited by 233
Activation and self‐tolerance of natural killer cells
Gasser, S., & Raulet, D. H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00460.x · Cited by 233
“Ectopic expression of NKG2D ligands in rare tumor cell lines that lack endogenous NKG2D ligands rendered the cells sensitive to NK cell-mediated lysis in vitro and resulted in tumor rejection in vivo (44, 45, 87).”
BackgroundSelf-citationWard, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 228
The innate immune response to tumors and its role in the induction of T‐cell immunity
Diefenbach, A., & Raulet, D. H. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18802.x · Cited by 228
Self-citationCoudert, J. D., Zimmer, J., Tomasello, E., Cebecauer, M., Colonna, M., Vivier, E., & Held, W. (2005) · Blood · doi:10.1182/blood-2005-03-0918 · Cited by 226
Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications
Levy, E. M., Roberti, M. P., & Mordoh, J. (2011) · BioMed Research International · doi:10.1155/2011/676198 · Cited by 219
“The lack of MHC class I expression [10] or the upregulation of NKG2D ligands [11, 12] can render tumor cells susceptible to NK cell-mediated lysis.”
BackgroundBoles, K. S., Barchet, W., Diacovo, T., Cella, M., & Colonna, M. (2005) · Blood · doi:10.1182/blood-2005-02-0817 · Cited by 208
NKG2D ligands as therapeutic targets.
(2013) · Europe PMC (PubMed Central) · Cited by 218
Killers 2.0: NK cell therapies at the forefront of cancer control
Hodgins, J. J., Khan, S. T., Park, M. M., Auer, R. C., & Ardolino, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129338 · Cited by 217
“Broadly speaking, activating receptors, including NKG2D, provide activating signals upon binding to stress-induced ligands on target cells, which is referred to as “induced-self recognition” (12, 13).”
BackgroundInnate Immunity and Cancer Pathophysiology
Maiorino, L., Daßler-Plenker, J., Sun, L., & Egeblad, M. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032221-115501 · Cited by 215
NK cell MHC class I specific receptors (KIR): from biology to clinical intervention
Thielens, A., Vivier, E., & Romagné, F. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.01.001 · Cited by 214
Immunobiology of Human NKG2D and Its Ligands
González, S., Groh, V., & Spies, T. (2006) · Current Topics in Microbiology and Immunology · doi:10.1007/3-540-27743-9_6 · Cited by 211
“dependent rejection of tumor cells by NK cells and primed cytotoxic T cells in syngeneic mice, thus reinforcing the potential significance of humanMICNKG2D in innate and adaptive immune responses against tumors (Cerwenka et al. 2001; Diefenbach et al. 2001).”
BackgroundMolecular mechanisms of natural killer cell activation in response to cellular stress
Chan, C. J., Smyth, M. J., & Martinet, L. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.26 · Cited by 213
MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo
Krmpotić, A., Busch, D. H., Bubić, I., Gebhardt, F., Hengel, H., Hasan, M., Scalzo, A. A., Koszinowski, U. H., & Jonjić, S. (2002) · Nature Immunology · doi:10.1038/ni799 · Cited by 208
Natural mechanisms protecting against cancer
Jakóbisiak, M., Lasek, W., & Gołąb, J. (2003) · Immunology Letters · doi:10.1016/j.imlet.2003.08.005 · Cited by 206
Garrity, D., Call, M. E., Feng, J., & Wucherpfennig, K. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502439102 · Cited by 205
Tricking the balance: NK cells in anti-cancer immunity
Pahl, J., & Cerwenka, A. (2017) · Immunobiology · doi:10.1016/j.imbio.2015.07.012 · Cited by 205
“Aside from their role in initial responses against nfection and cancer, it has become evident, that NK cells also ontribute to the induction of adaptive anti-cancer T cell as well s B cell responses (Diefenbach et al., 2001; Kelly et al., 2002; rebs et al., 2009; Smyth et al., 2005a,b).”
BackgroundLymphocyte activation via NKG2D: towards a new paradigm in immune recognition?
Vivier, E., Tomasello, E., & Paul, P. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00337-0 · Cited by 204
Nakamura, T., Miyabe, H., Hyodo, M., Sato, Y., Hayakawa, Y., & Harashima, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.026 · Cited by 198
“NKG2D clearly influences the NK cell mediated immune surveillance of experimentally induced tumors [33,34].”
BackgroundAsgarova, A., Asgarov, K., Godet, Y., Peixoto, P., Nadaradjane, A., Boyer-Guittaut, M., Galaine, J., Guenat, D., Mougey, V., Perrard, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1423170 · Cited by 199
NK cell self tolerance, responsiveness and missing self recognition
Shifrin, N., Raulet, D. H., & Ardolino, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.007 · Cited by 197
“[5] Diefenbach A, Jensen ER, Jamieson AM, Raulet DH.”
Self-citationEngineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., Kiessling, R., Blankenstein, T., Abken, H., & Charo, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804788105 · Cited by 197
“These included the use of allo NK cells (23), blocking the inhibitory signal (24), or triggering the activation receptors by using monoclonal antibodies or by genetic modification of tumor cells (11, 25, 26).”
BackgroundMcGilvray, R. W., Eagle, R. A., Watson, N. F. S., Al-Attar, A., Ball, G., Jafferji, I., Trowsdale, J., & Durrant, L. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0991 · Cited by 196
“In mouse models, it has been shown that tumor cell lines transfected with Rae1 are rejected in vivo via NKG2D-mediated immunity (18, 19).”
BackgroundNowbakht, P., Ionescu, M.-C. S., Rohner, A., Kalberer, C. P., Rossy, E., Mori, L., Cosman, D., De Libero, G., & Wodnar-Filipowicz, A. (2005) · Blood · doi:10.1182/blood-2004-07-2585 · Cited by 196
MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese, M. A., Platten, M., Lutz, S. Z., Naumann, U., Aulwurm, S., Bischof, F., Bühring, H. ‐., DICHGANS, J., Rammensee, H., Steinle, A., et al. (2003) · PubMed · Cited by 224
Paschen, A., Sucker, A., Hill, B., Moll, I., Zapatka, M., Nguyen, X. D., Sim, G. C., Gutmann, I., Hassel, J., Becker, J. C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0886 · Cited by 192
“When grafted into mice, tumor cells modified to express NKG2D ligands (NKG2DL) were rejected in contrast to nonmodified tumor cells (7, 8).”
BackgroundCytokine therapy reverses NK cell anergy in MHC-deficient tumors
Ardolino, M., Azimi, C. S., Iannello, A., Trevino, T. N., Horan, L., Zhang, L., Deng, W., Ring, A. M., Fischer, S., Garcia, K. C., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74337 · Cited by 191
“15, 16, and Figure 1A, top panel).”
InfluentialSelf-citationSuppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
Ruocco, M. G., Pilones, K. A., Kawashima, N., Cammer, M., Huang, J., Babb, J. S., Liu, M., Formenti, S. C., Dustin, M. L., & Demaria, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61931 · Cited by 187
“transplantable tumors, highlighting a critical role of the NKG2D receptor-ligand system in antitumor immunity (65).”
Innate lymphoid cells control signaling circuits to regulate tissue-specific immunity
Klose, C. S. N., & Artis, D. (2020) · Cell Research · doi:10.1038/s41422-020-0323-8 · Cited by 190
A mathematical model of tumor–immune interactions
Robertson-Tessi, M., El-Kareh, A., & Goriely, A. (2012) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.10.027 · Cited by 187
“The parameters r0 and k2 were taken from in vitro T-cell lysis data presented in Diefenbach et al. (2001), Dudley et al. (2002), and Thomas and Massagué (2005).”
MethodSustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways
Coudert, J. D., Scarpellino, L., Gros, F., Vivier, E., & Held, W. (2008) · Blood · doi:10.1182/blood-2007-07-100057 · Cited by 185
NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases
Zompi, S., Hamerman, J. A., Ogasawara, K., Schweighoffer, E., Tybulewicz, V. L. J., Di Santo, J. P., Lanier, L. L., & Colucci, F. (2003) · Nature Immunology · doi:10.1038/ni930 · Cited by 189
Junqueira-Kipnis, A. P., Kipnis, A., Jamieson, A., Juarrero, M. G., Diefenbach, A., Raulet, D. H., Turner, J., & Orme, I. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6039 · Cited by 184
Self-citationVariable receptors controlling activation and inhibition of NK cells
McQueen, K. L., & Parham, P. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00380-1 · Cited by 186
The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells
Sen Santara, S., Lee, D.-J., Crespo, Â., Hu, J. J., Walker, C., Ma, X., Zhang, Y., Chowdhury, S., Meza-Sosa, K. F., Lewandrowski, M., et al. (2023) · Nature · doi:10.1038/s41586-023-05912-0 · Cited by 187
Heinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., & Paschen, A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1977 · Cited by 187
“16 Discussion The NKG2D receptor allows cytotoxic lymphocytes to detect cellular stress associated with malignant transformation, which in turn can lead to tumor rejection as demonstrated in several mouse studies (2-7).”
BackgroundHayakawa, Y., Kelly, J. M., Westwood, J. A., Darcy, P. K., Diefenbach, A., Raulet, D., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5377 · Cited by 185
“This confirmed the finding that CD8 T cells participate in the rejection of RMA-Rae-1 tumor cells (20), in contrast to another report that only NK cells mediate rejection of RMA cells transduced with Rae-1 (21).”
BackgroundMethodResultSelf-citationTwo Human ULBP/RAET1 Molecules with Transmembrane Regions Are Ligands for NKG2D
Bacon, L., Eagle, R. A., Meyer, M., Easom, N., Young, N. T., & Trowsdale, J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1078 · Cited by 184
Targeting NK-cell checkpoints for cancer immunotherapy
Muntasell, A., Ochoa, M. C., Cordeiro, L., Berraondo, P., López-Díaz de Cerio, A., Cabo, M., López-Botet, M., & Melero, I. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.003 · Cited by 182
Improving Cancer Immunotherapy by Cell Membrane‐Camouflaged Nanoparticles
Zeng, Z., & Pu, K. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202004397 · Cited by 182
Wilcox, R. A., Tamada, K., Strome, S. E., & Chen, L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4230 · Cited by 181
Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita, H., Gilfillan, S., Colonna, M., & Smyth, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903225 · Cited by 180
“NKG2D is a primary activation receptor used by NK cells to detect and eliminate tumor cells (35).”
BackgroundTurnover and Proliferation of NK Cells in Steady State and Lymphopenic Conditions
Jamieson, A. M., Isnard, P., Dorfman, J. R., Coles, M. C., & Raulet, D. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.864 · Cited by 180
“Recent studies have shown that the NK cell population in mature mice is nearly devoid of cytolytic activity until activated by stimuli (priming) such as poly(I:C), viral infection, or target cells that express ligands such as Rae1 that stimulate NK cells (40, 41).”
BackgroundSelf-citationThe DNA Damage Response Arouses the Immune System
Gasser, S., & Raulet, D. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4603 · Cited by 178
“resulting, in some instances, in long-lasting T cell immunity (10).”
BackgroundSelf-citationImmune Recognition and Rejection of Allogeneic Skin Grafts
Benichou, G., Yamada, Y., Yun, S.-H., Lin, C., Fray, M., & Tocco, G. (2011) · Immunotherapy · doi:10.2217/imt.11.2 · Cited by 176
NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer
Smyth, M. J., Swann, J., Kelly, J. M., Cretney, E., Yokoyama, W. M., Diefenbach, A., Sayers, T. J., & Hayakawa, Y. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041522 · Cited by 169
“IL-2 also enhanced NK cell–mediated cytotoxicity of RMA-S-Rae1 (Fig.”
BackgroundMethodResultInfluentialSelf-citationLi, K., Mandai, M., Hamanishi, J., Matsumura, N., Suzuki, A., Yagi, H., Yamaguchi, K., Baba, T., Fujii, S., & Konishi, I. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0585-3 · Cited by 175
Cruz‐Munoz, M., Dong, Z., Shi, X., Zhang, S., & Veillette, A. (2009) · Nature Immunology · doi:10.1038/ni.1693 · Cited by 174
Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self
Ruggeri, L., Aversa, F., Martelli, M. F., & Velardi, A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00455.x · Cited by 172
Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair?
Vivier, E., Spits, H., & Cupedo, T. (2009) · Nature Reviews Immunology · doi:10.1038/nri2522 · Cited by 172
Zhang, B., Kracker, S., Yasuda, T., Casola, S., Vanneman, M., Hömig-Hölzel, C., Wang, Z., Derudder, E., Li, S., Chakraborty, T., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.031 · Cited by 172
“In addition, the stress antigen Rae-1, a ligand of amajor NK-activating receptor termed NKG2D (Diefenbach et al., 2001), was highly expressed on the surface of the LMP1 lymphoma cells (Figure 7B).”
A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity
Diefenbach, A., Hsia, J. K., Hsiung, M. B., & Raulet, D. H. (2003) · European Journal of Immunology · doi:10.1002/immu.200310012 · Cited by 170
Self-citationFan, Z., Yu, P., Wang, Y., Wang, Y., Fu, M. L., Liu, W., Sun, Y., & Fu, Y.-X. (2006) · Blood · doi:10.1182/blood-2005-08-3485 · Cited by 170
Epardaud, M., Elpek, K. G., Rubinstein, M. P., Yonekura, A.-R., Bellemare-Pelletier, A., Bronson, R., Hamerman, J. A., Goldrath, A. W., & Turley, S. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0045 · Cited by 167
Jinushi, M., Hodi, F. S., & Dranoff, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603503103 · Cited by 168
Deguine, J., Bréart, B., Lemaître, F., Santo, J. P. D., & Bousso, P. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.016 · Cited by 179
NKG2D ligands: unconventional MHC class I‐like molecules exploited by viruses and cancer
Cerwenka, A., & Lanier, L. L. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00070.x · Cited by 167
Natural killer cells: role in local tumor growth and metastasis
Jacobs, N., Langers, Renoux, Thiry, & Delvenne (2012) · Biologics: Targets and Therapy · doi:10.2147/btt.s23976 · Cited by 163
“Especially the lack of MHC-I expression, overexpression of NKG2D ligands (H60, Rae1β, Rae1δ, Rae1γ, Mult-1), or costimulatory signals makes the tumor more susceptible to lysis by NK cells.(84) Moreover, engagement of NCR complements NKG2D pathway in the killing of tumor cells by NK cells.”
Bugide, S., Green, M. R., & Wajapeyee, N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802691115 · Cited by 155
“NK cells recognize and bind to NK cell ligands expressed on target cells and induce their lysis (17, 18, 31).”
BackgroundInfluentialMathematical Model Creation for Cancer Chemo‐Immunotherapy
de Pillis, L., Fister, K. R., Gu, W., Collins, C., Daub, M., Gross, D., Moore, J., & Preskill, B. (2009) · Computational and Mathematical Methods in Medicine · doi:10.1080/17486700802216301 · Cited by 161
“31 £ 10 Day [12,14] b 1.”
InfluentialRegulation of ligands for the activating receptor NKG2D
Mistry, A. R., & O'Callaghan, C. A. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02652.x · Cited by 160
Erratum: Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.74 · Cited by 160
Mononuclear myeloid-derived “suppressor” cells express RAE-1 and activate natural killer cells
Nausch, N., Galani, I. E., Schlecker, E., & Cerwenka, A. (2008) · Blood · doi:10.1182/blood-2008-03-143776 · Cited by 151
NK Cells in the Tumor Microenvironment
Guillerey, C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_4 · Cited by 174
Dasgupta, S., Bhattacharya-Chatterjee, M., O’Malley, B. W., & Chatterjee, S. K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5541 · Cited by 158
“Two ligands, H60 and Rae1 are commonly expressed in NK susceptible mice tumors (21).”
BackgroundChimeric NK-receptor–bearing T cells mediate antitumor immunotherapy
Zhang, T., Lemoi, B. A., & Sentman, C. L. (2005) · Blood · doi:10.1182/blood-2004-11-4365 · Cited by 155
“reported that RMA cells with reduced levels of Rae-1β expression resulted in tumor growth and death of wildtype mice.(15) Our data demonstrate that chNKG2D-bearing T cells are effective against tumor cells with low levels of ligand expression and those that express endogenous NKG2D ligands.”
InfluentialRelease of MICB Molecules by Tumor Cells: Mechanism and Soluble MICB in Sera of Cancer Patients
Salih, H. R., Goehlsdorf, D., & Steinle, A. (2006) · Human Immunology · doi:10.1016/j.humimm.2006.02.008 · Cited by 178
Boissel, N., Rea, D., Tieng, V., Dulphy, N., Brun, M., Cayuela, J.-M., Rousselot, P., Tamouza, R., Le Bouteiller, P., Mahon, F.-X., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.5108 · Cited by 148
“Insufficient expression of these ligands by transfected tumor cells may reduce tumor rejection in mice (8).”
BackgroundNKG2D Ligands in Tumor Immunity: Two Sides of a Coin
Zhang, J., Basher, F., & Wu, J. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00097 · Cited by 146
“In vivo studies with experimental animals have demonstrated that ectopic expression of NKG2D ligands on tumor cells is sufficient to cause tumor rejection (9, 10).”
BackgroundLeveraging NKG2D Ligands in Immuno-Oncology
Fuertes, M. B., Domaica, C. I., & Zwirner, N. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713158 · Cited by 165
Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor
Shin, J. H., Zhang, L., Murillo-Sauca, O., Kim, J., Kohrt, H. E. K., Bui, J. D., & Sunwoo, J. B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302856110 · Cited by 148
“RMA-S is a murine lymphoma cell line that has reduced levels of MHC class I, and NK cells are both necessary and sufficient to control RMA-S tumor formation in WT mice (14).”
BackgroundKrmpotic, A., Hasan, M., Loewendorf, A., Saulig, T., Halenius, A., Lenac, T., Polic, B., Bubic, I., Kriegeskorte, A., Pernjak-Pugel, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041617 · Cited by 149
“NKG2D receptor triggering can override signals by MHC class I–specific inhibitory NK cell receptors (16, 17).”
BackgroundTumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor
Tahara-Hanaoka, S., Shibuya, K., Kai, H., Miyamoto, A., Morikawa, Y., Ohkochi, N., Honda, S.-I., & Shibuya, A. (2006) · Blood · doi:10.1182/blood-2005-04-1684 · Cited by 149
Schnurr, M. M., Scholz, C., Rothenfußer, S., Galambos, P., Dauer, M., Röbe, J., Endres, S., & Eigler, A. (2002) · PubMed · Cited by 147
von Strandmann, E. P., Hansen, H. P., Reiners, K. S., Schnell, R., Borchmann, P., Merkert, S., Simhadri, V. R., Draube, A., Reiser, M., Purr, I., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2177 · Cited by 157
MHC Class I Antigens and Immune Surveillance in Transformed Cells
Aptsiauri, N., Cabrera, T., Garcia‐Lora, A., Lopez‐Nevot, M. A., Ruiz‐Cabello, F., & Garrido, F. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(07)56005-5 · Cited by 145
Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric Oxide
Siemens, D. R., Hu, N., Sheikhi, A. K., Chung, E., Frederiksen, L. J., Pross, H., & Graham, C. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0054 · Cited by 138
“It has been reported that the strength of an antitumor immune response in mice is dependent on the levels of NKG2D ligands on the surface of tumor cells ( 17 ).”
BackgroundCerboni, C., Fionda, C., Soriani, A., Zingoni, A., Doria, M., Cippitelli, M., & Santoni, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00508 · Cited by 136
“CANCER CELLS The relevance of NKG2D in tumor surveillance has been demonstrated by in vivo experiments showing that overexpression of NKG2D ligands in cancer cells causes tumor rejection in mice (56, 57), and that NKG2D-deficient animals are defective in tumor surveillance in models of spontaneous malignancy (58).”
Elsner, L., Muppala, V., Gehrmann, M., Lozano, J., Malzahn, D., Bickeböller, H., Brunner, E., Zientkowska, M., Herrmann, T., Walter, L., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5523 · Cited by 140
“NKG2D has been shown to serve as an activating receptor triggering NK cell responses against tumors and expression of NKG2D ligands in tumors has been reported to induce tumor rejection (22, 45, 46).”
BackgroundNalle, S. C., & Turner, J. R. (2015) · Mucosal Immunology · doi:10.1038/mi.2015.40 · Cited by 151
“The signal could come from the T-cells themselves, as activated T-cells are known to upregulate ligands for the NK cell receptor NKG2D, such as members of the Rae1 family.(151,152) A non-mutually exclusive explanation is that NK cell cytoxicity is increased in response to the cytokine milieu after BMT.”
Backgroundde Kruijf, E. M., Sajet, A., van Nes, J. G. H., Putter, H., Smit, V. T. H. B. M., Eagle, R. A., Jafferji, I., Trowsdale, J., Liefers, G., van de Velde, C. J., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-24 · Cited by 148
“Recent studies have shown that NKG2D ligands may play an important role in cancer immunosurveillance and cancer immunoediting [8-10,15-22].”
BackgroundThe changing role of natural killer cells in solid organ rejection and tolerance.
Kitchens, W., Uehara, S., Chase, C., Colvin, R., Russell, P., & Madsen, J. (2006) · Transplantation · doi:10.1097/01.tp.0000202844.33794.0e · Cited by 143
The role of the NKG2D receptor for tumor immunity
Coudert, J. D., & Held, W. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.008 · Cited by 150
“[83] Diefenbach A, Jensen ER, Jamieson AM, Raulet DH.”
InfluentialHoldenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A., & Salih, H. R. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0167-1 · Cited by 152
“depending on NKG2DL surface levels [6], down-regu-”
Jin, F., Zhaozhen, W., Hu, X., Zhang, J., Zihe, G., Xiao, H., Junfang, Q., Chen, L., & Wang, Y. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0253 · Cited by 142
NF-κB regulation of endothelial cell function during LPS-induced toxemia and cancer
Kisseleva, T., Song, L., Vorontchikhina, M., Feirt, N., Kitajewski, J., & Schindler, C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27392 · Cited by 137
Metadata
- Authors
- Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Raulet, David H.
- Venue
- Nature
- Published
- 2001-09-13
- Volume
- 413
- Issue
- 6852
- Pages
- 165-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3900321
- OpenAlex
- W1595098530
- Cited by
- 1,083
- References
- 30
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 26 · 2023: 38 · 2022: 28 · 2021: 43 · 2020: 48 · 2019: 37 · 2018: 38 · 2017: 32 · 2016: 34 · 2015: 53 · 2014: 42 · 2013: 48 · 2012: 42
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI039642)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- NKG2D, Rae1, NKG2D ligands, natural killer cells, tumour immunity, tumor rejection, CD8+ T cells, cancer vaccines, MHC class I
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Immunity, Killer Cells, Natural, Ligands, Membrane Proteins, Mice, Inbred C57BL, Neoplasms, Receptors, Immunologic, Recombinant Proteins, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Minor Histocompatibility Antigens, CD8-Positive T-Lymphocytes, Mice, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.